{"prompt": "['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 49 of 51', 'Study ID RCB: 2020-A00652-37', 'European Medicines Agency (2017). Guideline on good pharmacovigilance practices (GVP)', 'Module VI - Collection, management and submission of reports of suspected adverse', 'reactions to medicinal products (Rev 2).', 'Feuerhahn, J., Blome, C., Radtke, M., and Augustin, M. (2012). Validation of the patient', 'benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis.', 'Archives of Dermatological Research 304, 433-441.', 'Finlay, A.Y., and Khan, G.K. (1994). Dermatology Life Quality Index (DLQI) - a simple practical', 'measure for routine clinical use. Clinical and Experimental Dermatology 19, 210-216.', 'Food and Drug Administration (2013). Guidance for Industry and FDA Staff. Best Practices for', 'Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic', 'Healthcare Data.', 'Forestier, B., Anthoine, E., Reguiai, Z., Fohrer, C., and Blanchin, M. (2019). A systematic', 'review of dimensions evaluating patient experience in chronic illness. Health and Quality of', 'Life Outcomes 17, 19-19.', 'Gelfand, J.M., Weinstein, R., Porter, S.B., Neimann, A.L., Berlin, J.A., and Margolis, D.J. (2005).', 'Prevalence and Treatment of Psoriasis in the United Kingdom: A Population-Based Study.', 'Archives of Dermatology 141, 1537-1541.', 'Huerta, C., Rivero, E., and Rodr\u00edguez, L.A.G. (2007). Incidence and Risk Factors for Psoriasis in', 'the General Population. Archives of Dermatology 143, 1559-1565.', 'Ippagunta, S.K., Gangwar, R., Finkelstein, D., Vogel, P., Pelletier, S., Gingras, S., Redecke, V.,', 'and H\u00e4cker, H. (2016). Keratinocytes contribute intrinsically to psoriasis upon loss of Tnip1', 'function. Proceedings of the National Academy of Sciences of the United States of America', '113, E6162-E6171.', 'Kerdel, F., and Zaiac, M. (2015). An evolution in switching therapy for psoriasis patients who', 'fail to meet treatment goals. Dermatologic Therapy 28, 390-403.', 'van de Kerkhof, P.C.M., Reich, K., Kavanaugh, A., Bachelez, H., Barker, J., Girolomoni, G.,', 'Langley, R.G., Paul, C.F., Puig, L., and Lebwohl, M.G. (2015). Physician perspectives in the', 'management of psoriasis and psoriatic arthritis: results from the population-based', 'Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. Journal of the European', 'Academy of Dermatology and Venereology : JEADV 29, 2002-2010.', 'Krueger, G., Koo, J., Lebwohl, M., Menter, A., Stern, R.S., and Rolstad, T. (2001). The Impact of', 'Psoriasis on Quality of Life: Results of a 1998 National Psoriasis Foundation Patient-', 'Membership Survey. Archives of Dermatology 137, 280-284.', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 50 of 51', 'Study ID RCB: 2020-A00652-37', 'Kurd, S.K., and Gelfand, J.M. (2009). The prevalence of previously diagnosed and', 'undiagnosed psoriasis in US adults: results from NHANES 2003-2004. Journal of the American', 'Academy of Dermatology 60, 218-224.', 'Lebwohl, M. (2018). Psoriasis. Annals of Internal Medicine 168, ITC49-ITC64.', 'Lebwohl, M., Strober, B., Menter, A., Gordon, K., Weglowska, J., Puig, L., Papp, K., Spelman,', 'L., Toth, D., Kerdel, F., et al. (2015). Phase 3 Studies Comparing Brodalumab with', 'Ustekinumab in Psoriasis. N Engl J Med 373, 1318-1328.', 'Li, J., and Fine, J. (2004). On sample size for sensitivity and specificity in prospective', 'diagnostic accuracy studies. Statistics in Medicine 23, 2537-2550.', 'Lowes, M.A., Bowcock, A.M., and Krueger, J.G. (2007). Pathogenesis and therapy of psoriasis.', 'Nature 445, 866.', 'Public Policy Committee, I.S. of P. (2016). Guidelines for good pharmacoepidemiology', 'practice (GPP). Pharmacoepidemiology and Drug Safety 25, 2-10.', 'Puig, L., Thom, H., Mollon, P., Tian, H., and Ramakrishna, G.S. (2017). Clear or almost clear', 'skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic', 'review and meta-analysis. Journal of the European Academy of Dermatology and', 'Venereology 31, 213-220.', 'Richard, M.-A., Corgibet, F., Beylot-Barry, M., Barbaud, A., Bodemer, C., Chaussade, V.,', \"D'Incan, M., Joly, P., Leccia, M.T., Meurant, J.M., et al. (2018). Sex- and age-adjusted\", 'prevalence estimates of five chronic inflammatory skin diseases in France: results of the', '\" OBJECTIFS PEAU \" study. Journal of the European Academy of Dermatology and', 'Venereology 32, 1967-1971.', 'Sampogna, F., Puig, L., Spuls, P., Girolomoni, G., Radtke, M.A., Kirby, B., Brunori, M.,', 'Bergmans, P., Smirnov, P., Rundle, J., et al. (2017). Prevalence of alexithymia in patients with', 'psoriasis and its association with disease burden: a multicentre observational study. British', 'Journal of Dermatology 176, 1195-1203.', 'Stern, R.S., Nijsten, T., Feldman, S.R., Margolis, D.J., and Rolstad, T. (2004). Psoriasis Is', 'Common, Carries a Substantial Burden Even When Not Extensive, and Is Associated with', 'Widespread Treatment Dissatisfaction. Journal of Investigative Dermatology Symposium', 'Proceedings 9, 136-139.', 'The European Federation of Pharmaceutical Industries and Associations (2008). EFPIA HCP', 'CODE. EFPIA code on the promotion of prescription-only medicines to, and interactions with,', 'healthcare professionals.', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 51 of 51', 'Study ID RCB: 2020-A00652-37', 'World Medical Association (2013). World Medical Association Declaration of HelsinkiEthical', 'Principles for Medical ResearchInvolving Human Subjects.', 'Annex 1. PSO-TARGET Component Grid', 'Physical', 'Subjective', 'Relational/social', 'Therapeutic', 'Not be', 'Think less or not at all about', 'Spend quality time with family,', 'Need to think less about', 'limited/handicaped by', 'the disease', 'friends or colleagues', 'treatment and care', 'the pain', 'Do not feel any', 'functional discomfort', 'Do not feel any anxiety from', 'Not caring about what people think', 'Encounter very few, if any,', '(itching, rash) in my', 'the disease', 'about me', 'drug discomfort', 'daily activities', 'Have freedom of', 'Feel serene, have peace of', 'movement and', 'Have a fulfilling intimate life', 'To be cured quickly', 'mind', 'activities', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']", "completion": ""}